Management

nopicture.jpg
 

Thomas h. pedersen, CEO

Thomas H. Pedersen has an academic background in skeletal muscle physiology and neuromuscular disease. He holds a PhD in Physiology from Aarhus University and he did two years of post doctoral work at Cambridge University. Thomas has years of experience in cellular electrophysiology and he has published more than 30 high-ranking papers including a first author paper in Science and several papers in The Journal of General Physiology. NMD Pharma was founded on scientific discoveries obtained in the Muscle Laboratory at Aarhus University in which Thomas holds a position as Associate Professor.

 
nopicture.jpg
 
2019-03-11-NMDPORTRAITS-3337.jpg
 
2019-03-11-NMDPORTRAITS-3282.jpg

claus E. olesen, CBo

Claus Olesen has a PhD in Physiology and Biophysics from Aarhus University. His academic work focus on structural biology and function of membrane proteins and he has several publications including two first author papers in Science and Nature. Claus has been involved in several drug development projects in both academic and industrial settings. He is co-founder of Pcovery ApS and he is CEO of Initiator Pharma. Claus serves as Business Developer at Aarhus University. He is former professional sailor and he competed in Americas Cup for Sweden in 2003 and represented Denmark at two Olympics.

 

Eva Chin, CDO

Eva obtained her Ph.D. in Physiology from the University of Waterloo in Canada and completed post-doctoral training at the University of Sydney, Australia and UT Southwestern Medical Center in Dallas, focusing on the role of intracellular calcium in muscle fatigue, muscle fiber type determination and muscle plasticity. Her career has spanned the academic and pharmaceutical industries, with positions at Pfizer, the University of Maryland, MyoTherapeutics and Cytokinetics.While at Pfizer Eva shifted her focus to the discovery and development of muscle-targeted therapies. Her career has increasingly focused on targeting the underlying skeletal muscle pathologies in rare neuromuscular diseases, including muscular dystrophy, amyotrophic lateral sclerosis and spinal muscular atrophy. Eva has also been a team leader in late stage research to early phase clinical development programs across a span of therapeutic areas including cardiovascular disease, obesity, diabetes and osteoporosis. Prior to joining NMD Pharma she led seven programs from candidate nomination to Ph.1 or Ph.2 proof of concept milestones. Eva has 49 peer-reviewed publications and more than 100 conference abstracts and presentations focusing on skeletal muscle fatigue and disease mechanisms for metabolic disease, aging and neuromuscular diseases.

 

John Hutchison, Consulting CMO

John is a UK registered physician with thirty years of R&D experience in the pharmaceutical industry, in both large and small companies. He has worked in all stages of drug development up to and beyond product approval, and in the past has led teams covering all aspects of research and development. His particular expertise is in translational medicine using biomarkers to inform development strategy going forwards, with an emphasis on proof of concept in man. John’s main therapeutic interests have been in CNS diseases (neurology and psychiatry) and pain, although he has led programmes in regenerative medicine, sensory disorders and cardiovascular disease at various times in the past. John was educated at the University of Liverpool, where he was awarded a first class honours degree and a PhD in Physiology, and at Leicester University Medical School where he graduated in 1985. John is a Fellow of the Royal College of Physicians (London), and a Fellow of the Faculty of Pharmaceutical Medicine.

 

Board

 
Pic_Anja_New.jpg

Patrick Vink, Chairman

Patrick Vink has more than 30 years of experience in life sciences industry. He was COO of Cubist Inc and served as Senior Vice-President of global Institutional Business at Mylan. Earlier he was head of the global business unit Biologics at Sandoz, Head of international operations at Biogen and head of worldwide Cardio-vascular and Thrombosis marketing at Sanafi-Synthelabo. Patrick is an advisor to the Life Science Industry, Chairman of Acacia Pharma, Targovax Oy and member of the Board of several publicly listed companies. Patrick is MD from University of Leiden and holds a MBA from University of Rochester and Rotterdam.

 

ANJA HARMEIER, BOD

Anja is an Investment Manager at the Roche Venture Fund in Basel. She is a member of the board of directors of Macrolide Pharmaceuticals, Opsona Therapeutics, Minoryx Therapeutics and NMD Pharma. Anja has experience in various roles in academic research, as an entrepreneur, and in drug development at F. Hoffmann- La Roche Ltd. Anja lead various programs using different modalities in the areas of neuroscience, metabolic diseases and in rare diseases. 

Anja holds an MSc in Biology from the Technical University of Munich and earned her PhD from the Free University of Berlin in Biochemistry studying the neurotoxicity of Amyloid beta and its prevention. In addition, Anja got her MBA with a focus on healthcare management from Instituto Empresa (IE) in Madrid.

 
 
Fiona.jpg

Christian E. Elling, Bod

Christian joined Lundbeckfonden in 2012 and leads early stage biotech investment unit Lundbeckfonden Emerge. He is a member of the board of directors of IO Biotech, NMD Pharma, CEO of Insusense Therapeutics and former member of the board of directors of EpiTherapeutics and Inagen. Christian was co-founder, Vice President of Biology and Development and later CEO of 7TM Pharma. Christian holds a PhD in Biochemistry and Pharmacology from University of Copenhagen, Denmark. Christian has published more than twenty papers and reviews.

 

Fiona MacLaughlin, BOD

Fiona is Director at Inkef Capital in Amsterdam and a member of the Board of Directors of NMD Pharma, Calypso Biotech and GTX Medical. Previously, Fiona was at Advent Life Sciences, during which time she co-founded Boston-based Arrakis Therapeutics Inc. and contributed to building companies Capella Therapeutics and Levicept. Her early interest in innovation grew from her prior role in the Technology Transfer Division of the Wellcome Trust where she evaluated early stage product development opportunities and investments for Translational Funding and established a £45M “R&D for Affordable Healthcare” fund for developing affordable technologies together with the Government of India. She has more than a decade of experience in biotech R&D. Fiona is a Pharmacist and has a PhD in Drug delivery (University of Nottingham, UK).

 
 
Jeremy.jpg
 

Morten G. Døssing, BOD

Morten joined Novo Seeds in 2016 as Investment Director. Prior to Novo, Morten was Director of Corporate Development at H. Lundbeck A/S where he was involved in M&A, corporate strategy, BD&L, portfolio management and equity investments. At Lundbeck Morten led acquisition of orphan neurology company Chelsea Therapeutics for 658 USD m and was involved in a range of other deals including the 1.8 USD Bn alliance with Otsuka Pharmaceuticals as well as equity investments and spinouts. Before Lundbeck, Morten worked as commercial manager in technology transfer to commercialize and establish new companies in biotech and medtech. Morten holds an MSc in Human Biology from the University of Copenhagen.

 

 

Jeremy P Springhorn, BOD

Jeremy has more than 25 years of senior leadership experience in the biotech industry. He is currently serving as the Chief Business Officer at Syros Pharmaceuticals. Prior to Syros, he was Partner at Flagship Pioneering where is he was focused on Corporate Development across the Portfolio. Prior to Flagship, Jeremy spent more than 20 years at Alexion where he was one of the original scientists as well as one of the inventors of Soliris. During his time at Alexion, he transitioned from R&D, ultimately building and then leading the Corporate Development Group. In that role, Jeremy led over $5B in deal value including the acquisitions of Enobia Pharma, Taligen Therapeutics and Orphatec. Jeremy also headed up strategic planning as Alexion transitioned from a development to a global commercial-stage company. Prior to 1992, Jeremy was a postdoctoral research fellow at the Brigham and Women's Hospital and received his Ph.D. from Louisiana State University Medical Center in New Orleans and his B.A. from Colby College. He currently serves on the Board of Directors of uniQure N.V. and the Board of Advisors for Mythic Therapeutics, Inc.